Pfizer CentreOne Expands Fill-Finish Services

Pfizer CentreOne, a global contract manufacturing organization embedded within Pfizer, has expanded its fill-finish services to its Kalamazoo, MI, site. Along with vial-filling of small molecules and biologics, the facility also provides vial-filling of sterile suspensions, expanding Pfizer CentreOne’s service portfolio. 

"Kalamazoo was the obvious choice for expansion of our fill-finish services," said Peter Stevenson, vice president and general manager, Pfizer CentreOne. "Our Kalamazoo colleagues have been doing contract manufacturing for over 40 years on the API side. It’s part of the culture and this is also one of Pfizer’s premier sterile-injectables sites. It’s a natural fit." 

With more than 65 years of experience in injectables fill-finish, the Kalamazoo site currently supplies drugs to more than 100 countries around the globe. Services at the Kalamazoo site encompass: small molecules and biologics; sterile suspensions; potent and controlled substances; aqueous and oil-based formulations; lyophilization; and vials 1-100mL; bulk formulation <1-1600 liters.
 
The Kalamazoo facility has dedicated, onsite technical, manufacturing science, regulatory affairs and quality teams. Over the last five years, they’ve transferred 37 customer and Pfizer compounds into the facility. Among Kalamazoo’s extensive scientific resources are experts in API processes who know how to solve complex issues with active ingredients; and a team of commodities experts who trouble-shoot problems with stoppers, glass and excipients.

"Our biopharma partners will be in good hands at Kalamazoo with a dedicated Pfizer CentreOne team by their side who deeply understand their needs, who can leverage a world of top-flight resources at the site on their behalf," said Stevenson.